TENAYA THERAPEUTICS INC (TNYA)

US87990A1060 - Common Stock

2.38  +0.22 (+10.19%)

After market: 2.35 -0.03 (-1.26%)

Fundamental Rating

2

Taking everything into account, TNYA scores 2 out of 10 in our fundamental rating. TNYA was compared to 565 industry peers in the Biotechnology industry. While TNYA seems to be doing ok healthwise, there are quite some concerns on its profitability. TNYA has a expensive valuation and it also scores bad on growth.



0

1. Profitability

1.1 Basic Checks

In the past year TNYA has reported negative net income.
In the past year TNYA has reported a negative cash flow from operations.
TNYA had negative earnings in each of the past 5 years.
In the past 5 years TNYA always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -83.39%, TNYA is not doing good in the industry: 72.01% of the companies in the same industry are doing better.
TNYA has a Return On Equity of -104.11%. This is comparable to the rest of the industry: TNYA outperforms 45.10% of its industry peers.
Industry RankSector Rank
ROA -83.39%
ROE -104.11%
ROIC N/A
ROA(3y)-46.75%
ROA(5y)-47.04%
ROE(3y)-55.31%
ROE(5y)-56.6%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

TNYA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

TNYA has more shares outstanding than it did 1 year ago.
TNYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -3.51, we must say that TNYA is in the distress zone and has some risk of bankruptcy.
TNYA has a Altman-Z score of -3.51. This is comparable to the rest of the industry: TNYA outperforms 46.35% of its industry peers.
TNYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.51
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

TNYA has a Current Ratio of 5.27. This indicates that TNYA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.27, TNYA perfoms like the industry average, outperforming 57.22% of the companies in the same industry.
TNYA has a Quick Ratio of 5.27. This indicates that TNYA is financially healthy and has no problem in meeting its short term obligations.
TNYA has a Quick ratio of 5.27. This is comparable to the rest of the industry: TNYA outperforms 58.11% of its industry peers.
Industry RankSector Rank
Current Ratio 5.27
Quick Ratio 5.27

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.40% over the past year.
EPS 1Y (TTM)23.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TNYA will show a very strong growth in Earnings Per Share. The EPS will grow by 35.69% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.83%
EPS Next 2Y6.57%
EPS Next 3Y5.32%
EPS Next 5Y35.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

TNYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TNYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.57%
EPS Next 3Y5.32%

0

5. Dividend

5.1 Amount

No dividends for TNYA!.
Industry RankSector Rank
Dividend Yield N/A

TENAYA THERAPEUTICS INC

NASDAQ:TNYA (11/22/2024, 8:09:02 PM)

After market: 2.35 -0.03 (-1.26%)

2.38

+0.22 (+10.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap188.54M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -83.39%
ROE -104.11%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.27
Quick Ratio 5.27
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)23.4%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y14.83%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y